Rivaroxaban is a factor Xa inhibitor used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). May also be used as thrombosis prophylaxis in specific situations. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor.
- Mechanism
- Curator reviewed
Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.
- Primary indication
- Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial...Curator reviewed · 17 structured indications
- Formula / weight
- C19H18ClN3O5S · 435.881 g/mol (avg)
- First approval
- Canada, 2008 · United States, 2011 · European Union, 2016
- Code names
- BAY 59-7939 · JNJ-39039039
- Brand names
Resolves to
KGFYHTZWPPHNLQ-AWEZNQCLSA-NSMILESClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=OWhat you can answer from here — as of June 15, 2026
Which drugs share a target with Rivaroxaban, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account